Literature DB >> 16434062

Non-invasive evaluation of endothelial dysfunction in uncomplicated obesity: relationship with insulin resistance.

Giuseppe Pasimeni1, Maria Cristina Ribaudo, Danila Capoccia, Fabio Rossi, Cora Bertone, Frida Leonetti, Vittorio Santiemma.   

Abstract

Obesity is associated with increased cardiovascular morbidity and amortality. Endothelial dysfunction, involved in the pathogenesis of cardiovascular events, has been demonstrated in obese patients with invasive techniques requiring artery catheterization. The aim of our investigation was to evaluate, with a non-invasive method readily employable on clinical grounds, impaired vasodilatation and its relationship with insulin resistance in uncomplicated obesity. 15 uncomplicated obese subjects (BMI = 36.6 +/- 3.2) and 10 lean controls (BMI = 22.9 +/- 1.25) were enrolled in this study. All subjects underwent measurement of endothelium-dependent (FBFr) vasodilatation by forearm venous occlusion pletysmography after increasing times of ischemia, and measurement of insulin sensitivity by the euglycemic hyperinsulinemic clamp technique (M index), by fasting glucose and insulin (HOMA-IR) and by oral glucose tolerance test (ISI index). Endothelium-independent (N-FBFr) vasodilatation was assessed as well. The FBFr was markedly blunted in obese patients versus lean controls (30 s: 2.12 +/- 0.34 vs. 3.63 +/- 0.22, P < 0.01; 60 s: 2.34 +/- 0.42 vs. 3.82 +/- 0.53, P < 0.01; 180 s: 3.20 +/- 0.45 vs. 7.15 +/- 0.35, P < 0.01; 300 s: 4.08 +/- 0.94 vs. 14.1 +/- 0.82, P < 0.001). The N-FBFr was not different in the two groups. High correlation was found between M index and FBFr at all ischemia times. HOMA-IR and ISI were not related with FBFr. The non-invasive evaluation of endothelial dysfunction by a simple and reliable method based on venous occlusive plethysmography shows high correlation between impaired endothelium-dependent vasodilatation and insulin resistance in uncomplicated obesity. This non-invasive test of endothelial function may be routinely performed in the assessment of cardiovascular risk in uncomplicated obesity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16434062     DOI: 10.1016/j.mvr.2005.12.001

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  7 in total

1.  Functional capillary rarefaction in mild blood pressure elevation.

Authors:  Cynthia Cheng; James J Diamond; Bonita Falkner
Journal:  Clin Transl Sci       Date:  2008-05       Impact factor: 4.689

Review 2.  Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications.

Authors:  Corey E Tabit; William B Chung; Naomi M Hamburg; Joseph A Vita
Journal:  Rev Endocr Metab Disord       Date:  2010-03       Impact factor: 6.514

3.  Repeatability of a dual gradient-recalled echo MRI method for monitoring post-isometric contraction blood volume and oxygenation changes.

Authors:  O A Sanchez; E A Louie; E A Copenhaver; B M Damon
Journal:  NMR Biomed       Date:  2009-08       Impact factor: 4.044

4.  Capillary rarefaction in treated and untreated hypertensive subjects.

Authors:  Cynthia Cheng; Constantine Daskalakis; Bonita Falkner
Journal:  Ther Adv Cardiovasc Dis       Date:  2008-04

5.  Association of capillary density and function measures with blood pressure, fasting plasma glucose, and insulin sensitivity.

Authors:  Cynthia Cheng; Constantine Daskalakis; Bonita Falkner
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-02-01       Impact factor: 3.738

6.  Mediterranean diet and insulin sensitivity, lipid profile and blood pressure levels, in overweight and obese people; the Attica study.

Authors:  Natalia Tzima; Christos Pitsavos; Demosthenes B Panagiotakos; John Skoumas; Antonis Zampelas; Christina Chrysohoou; Christodoulos Stefanadis
Journal:  Lipids Health Dis       Date:  2007-09-19       Impact factor: 3.876

Review 7.  Vitamin D & endothelial function.

Authors:  A Alyami; M J Soares; J L Sherriff; J C Mamo
Journal:  Indian J Med Res       Date:  2014-10       Impact factor: 2.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.